Minoxidil topique 2 % face à Minoxidil topique 5 %

baselinethroughweek24in67.7%ofparticipantsin the5%MTFarmcomparedwith56.1%ofparticipants inthe2%MTSarm(Fig5,A).Hairvolumedecreased in 5.4% and 10.5%, respectively, of the participants

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

baselinethroughweek24in67.7%ofparticipantsin the5%MTFarmcomparedwith56.1%ofparticipants inthe2%MTSarm(Fig5,A).Hairvolumedecreased in 5.4% and 10.5%, respectively, of the participants

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

baselinethroughweek24in67.7%ofparticipantsin the5%MTFarmcomparedwith56.1%ofparticipants inthe2%MTSarm(Fig5,A).Hairvolumedecreased in 5.4% and 10.5%, respectively, of the participants

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

baselinethroughweek24in67.7%ofparticipantsin the5%MTFarmcomparedwith56.1%ofparticipants inthe2%MTSarm(Fig5,A).Hairvolumedecreased in 5.4% and 10.5%, respectively, of the participants

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

B). At the end of the study, 73.2% of participants randomizedto5%MTFreported anincrease inhair volume compared with 80.7% of participants ran-

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

B). At the end of the study, 73.2% of participants randomizedto5%MTFreported anincrease inhair volume compared with 80.7% of participants ran-

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

and28.4hairs/cm2inthe2%MTSgroup(SD19.13); this difference was not significant (P = .441). This representsameanincreaseinhaircountof16.2%in the 5% MTF group and a 13.8% increase in the 2%

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

and28.4hairs/cm2inthe2%MTSgroup(SD19.13); this difference was not significant (P = .441). This representsameanincreaseinhaircountof16.2%in the 5% MTF group and a 13.8% increase in the 2%

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

events). Hair shedding occurred in 17.5% of all participants in the 2% MTS group compared with 12.5%inthe5%MTFpopulation.Headache,possibly relatedtostudymedication,wasreportedby3.6%of theparticipantsrandomizedto5%MTFandby7.0% of the participants randomized to 2% MTS. A slight

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

events). Hair shedding occurred in 17.5% of all participants in the 2% MTS group compared with 12.5%inthe5%MTFpopulation.Headache,possibly relatedtostudymedication,wasreportedby3.6%of theparticipantsrandomizedto5%MTFandby7.0% of the participants randomized to 2% MTS. A slight

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

2-levelincrease.Interestingly,frequencyofmanifes- tation of facial hypertrichosis in the sideburn area was significantly higher in the 2% MTS group com-

Citation complémentaire (valeur)

paredwiththe5%MTFgroup(2%MTSn=15,26%; 5%MTFn=6,11%;P\.033).However,inthetemple

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

2-levelincrease.Interestingly,frequencyofmanifes- tation of facial hypertrichosis in the sideburn area was significantly higher in the 2% MTS group com-

Citation complémentaire (valeur)

paredwiththe5%MTFgroup(2%MTSn=15,26%; 5%MTFn=6,11%;P\.033).However,inthetemple

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Citation complémentaire (valeur)

erythema (10.7% and 7.0%, respectively), burning/-

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Citation complémentaire (valeur)

erythema (10.7% and 7.0%, respectively), burning/-

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

events). Hair shedding occurred in 17.5% of all participants in the 2% MTS group compared with 12.5%inthe5%MTFpopulation.Headache,possibly relatedtostudymedication,wasreportedby3.6%of theparticipantsrandomizedto5%MTFandby7.0% of the participants randomized to 2% MTS. A slight

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

events). Hair shedding occurred in 17.5% of all participants in the 2% MTS group compared with 12.5%inthe5%MTFpopulation.Headache,possibly relatedtostudymedication,wasreportedby3.6%of theparticipantsrandomizedto5%MTFandby7.0% of the participants randomized to 2% MTS. A slight

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

n=1,2%). Localintolerance. ThetotalincidenceofLIwas significantly lower in the 5% MTF group (P = .046). The rate of mild-to-moderate scalp pruritus, as determined by the study investigators, was signifi- cantlylowerinthe5%MTFgroup(16.1%)thaninthe 2%MTSgroup(36.8%;P=.012).Inaddition,therate of dandruff was significantly lower in the 5% MTF group(5.4%)thaninthe2%MTSgroup(17.5%;P= .042). The rates of other LIs were generally similar

Blume-Peytavi U, Hillmann K, Dietz E et al.. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. Journal of the American Academy of Dermatology 2011, DOI 10.1016/j.jaad.2010.09.724. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator) Secondary Benefitfromtreatment(patient)† 60.0(cid:3)27.6 50.5(cid:3)32.5 Benefitfromtreatment 42.0(cid:3)27.1 37.4(cid:3)30.1 (investigator)†

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004 41.8(cid:3)29.9 .029‡ (cid:2).001‡ .092† 30.2(cid:3)27.0 .331‡ .022‡ .124†

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator) Secondary Benefitfromtreatment(patient)† 60.0(cid:3)27.6 50.5(cid:3)32.5 Benefitfromtreatment 42.0(cid:3)27.1 37.4(cid:3)30.1 (investigator)†

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004 41.8(cid:3)29.9 .029‡ (cid:2).001‡ .092† 30.2(cid:3)27.0 .331‡ .022‡ .124†

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator) Secondary Benefitfromtreatment(patient)† 60.0(cid:3)27.6 50.5(cid:3)32.5

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004 41.8(cid:3)29.9 .029‡ (cid:2).001‡ .092†

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator) Secondary Benefitfromtreatment(patient)† 60.0(cid:3)27.6 50.5(cid:3)32.5

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004 41.8(cid:3)29.9 .029‡ (cid:2).001‡ .092†

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)*

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)*

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIV.Efficacyresultsatallevaluationtimepoints(efficacyevaluablepopulation) Mean((cid:2)SD)changefrombaseline Treatment PairwisecomparisonPvalue Endpoint/Timepoint 5%Minoxidil 2%Minoxidil Nonvellushaircount Week8 21.7(cid:3)18.8 18.3(cid:3)19.0 Week16 36.0(cid:3)22.5 35.9(cid:3)21.7 Week32 27.1(cid:3)23.1 26.7(cid:3)20.3 Week48 24.5(cid:3)21.9 20.7(cid:3)17.6

Citation complémentaire (significativite)

Comparison 5%vs 5%vs 2%vs Placebo Pvalue 2% Placebo Placebo 11.1(cid:3)18.6 .010 .286 .002 .024 20.0(cid:3)19.8 (cid:2).001 .936 (cid:2).001 (cid:2).001 15.2(cid:3)16.8 .004 .928 .002 .002

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline)

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline)

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator)

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacyevaluablepopulation) Mean(cid:2)SD Efficacyendpoints 5%Minoxidil 2%Minoxidil Primary Nonvellushaircount(mean 24.5(cid:3)21.9 20.7(cid:3)17.6 changefrombaseline) Nonvellushaircount(mean 26.0(cid:3)19.5 20.7(cid:3)17.6 changefrombaseline) excludingoutlierpatients Changeinhairgrowth/scalp 68.1(cid:3)17.9 62.9(cid:3)16.7 coverage(patient)* Changeinhairgrowth/scalp 11.7(cid:3)17.2 10.3(cid:3)17.0 coverage(investigator)

Citation complémentaire (significativite)

PairwisecomparisonPvalue* 5%vs 5%vs 2%vs Placebo 2% placebo placebo 9.4(cid:3)14.6 .129 (cid:2).001 (cid:2).001 9.4(cid:3)14.6 .031 (cid:2).001 (cid:2).001 58.3(cid:3)18.2 .062 (cid:2).001 .057 2.2(cid:3)17.9 .608 .001 .004

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Drug-related cardiovascular adverse events (ie, palpitations,chestpain)werereportedfor2(1%)of the153patientsinthe5%topicalminoxidilgroup,2 (1%) of the 154 patients in the 2% topical minoxidil group, and 2 (3%) of the 74 patients in the placebo

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Drug-related cardiovascular adverse events (ie, palpitations,chestpain)werereportedfor2(1%)of the153patientsinthe5%topicalminoxidilgroup,2 (1%) of the 154 patients in the 2% topical minoxidil group, and 2 (3%) of the 74 patients in the placebo

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In reply to specific questioning by the in- vestigatorofanynewhairgrowthinareasotherthan the scalp, 71 (46%) of the 153 patients in the 5% 550 Lucky et al Fig 4. Clinical photographs of patients treated solution(TMS)(middle),and5%TMS(bottom). topicalminoxidilgroup,34(22%)ofthe154patients in the 2% topical minoxidil group, and 12 (16%) of

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

In reply to specific questioning by the in- vestigatorofanynewhairgrowthinareasotherthan the scalp, 71 (46%) of the 153 patients in the 5% 550 Lucky et al Fig 4. Clinical photographs of patients treated solution(TMS)(middle),and5%TMS(bottom). topicalminoxidilgroup,34(22%)ofthe154patients in the 2% topical minoxidil group, and 12 (16%) of

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Headachewasthenextmostcommonlyreported drug-related adverse event, affecting 3 (2%) of the 153patientsinthe5%topicalminoxidilgroupand6 (4%) of the 154 patients in the 2% topical minoxidil group; no patients in the placebo group reported

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Headachewasthenextmostcommonlyreported drug-related adverse event, affecting 3 (2%) of the 153patientsinthe5%topicalminoxidilgroupand6 (4%) of the 154 patients in the 2% topical minoxidil group; no patients in the placebo group reported

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The most frequent drug-related derma- tologic event was pruritus, affecting 8 (5%) of 153 patients in the 5% topical minoxidil group, 1 (0.6%) of 154 patients in the 2% topical minoxidil group, and 2 (3%) of 74 patients in the placebo group. In

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The most frequent drug-related derma- tologic event was pruritus, affecting 8 (5%) of 153 patients in the 5% topical minoxidil group, 1 (0.6%) of 154 patients in the 2% topical minoxidil group, and 2 (3%) of 74 patients in the placebo group. In

Lucky AW, Piacquadio DJ, Ditre CM et al.. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. J Am Acad Dermatol 2004, DOI 10.1016/j.jaad.2003.06.014. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

For the first reviewer, the percentages of pa- JAMACADDERMATOL SEPTEMBER2002 tients with hair regrowth at 48 weeks were 62% (86/139 patients), 44% (62/142 patients), and 30% (21/71 patients) in the 5% topical minoxidil, 2% topicalminoxidil,andplacebogroups,respectively.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

For the first reviewer, the percentages of pa- JAMACADDERMATOL SEPTEMBER2002 tients with hair regrowth at 48 weeks were 62% (86/139 patients), 44% (62/142 patients), and 30% (21/71 patients) in the 5% topical minoxidil, 2% topicalminoxidil,andplacebogroups,respectively.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Thepercentagesofpatientswithhairregrowthat48 weeks for the second reviewer were 54% (75/139 patients), 38% (54/142 patients), and 17% (12/71 patients) in the 5% topical minoxidil, 2% topical minoxidil,andplacebogroups,respectively.Greater

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Thepercentagesofpatientswithhairregrowthat48 weeks for the second reviewer were 54% (75/139 patients), 38% (54/142 patients), and 17% (12/71 patients) in the 5% topical minoxidil, 2% topical minoxidil,andplacebogroups,respectively.Greater

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableIII.Summaryofefficacyatweek48(efficacy-evaluablepopulation) Efficacyendpoints 5%Minoxidil Primary Nonvellushaircount(meanchange 18.6(cid:4)25.4 frombaseline) Changeinscalpcoverage(patient)† 62.0(cid:4)17.0 Benefitfromtreatment(patient)‡ 50.5(cid:4)28.6 Secondary Changeinscalpcoverage 12.3(cid:4)23.1 (investigator)(calculatedmean changefrombaseline) Benefitfromtreatment(investigator)‡ 33.7(cid:4)28.2 TreatmentbenefitS/Eratio(patient)§ 0.83(cid:4)0.61 S/E,Satisfaction/expectation;VAS,visualanalogscale. Mean(cid:2)SD PairwisecomparisonPvalue* 5%vs 2%vs 2%Minoxidil Placebo 5%vs2% Placebo Placebo 12.7(cid:4)20.7 3.9(cid:4)21.7 .025 (cid:3).001 .013 56.9(cid:4)11.0 51.0(cid:4)14.9 .002 (cid:3).001 .009 41.2(cid:4)25.3 26.1(cid:4)27.9 .004 (cid:3).001 (cid:3).001 7.0(cid:4)20.4 2.5(cid:4)19.5 .042 .002 .157 30.2(cid:4)28.4 12.6(cid:4)20.3 .342 (cid:3).001 (cid:3).001 0.72(cid:4)0.60 0.41(cid:4)0.42 .071 (cid:3).001 .001

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

According to the investigators’ assessment of signs and symptoms of contact dermatitis (ie, sting- ing/burning, itching, dryness/scaling), severe scalp symptoms were more prevalent in the 5% topical minoxidilgroup(10/157patients,6%)thaninthe2% topical minoxidil group (2/158 patients, 1%) and placebogroup(0/78patients,0%)

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

According to the investigators’ assessment of signs and symptoms of contact dermatitis (ie, sting- ing/burning, itching, dryness/scaling), severe scalp symptoms were more prevalent in the 5% topical minoxidilgroup(10/157patients,6%)thaninthe2% topical minoxidil group (2/158 patients, 1%) and placebogroup(0/78patients,0%)

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The occurrence of cardiovascular adverse events (ie, chest pain, palpitations, increase in blood pres- sure, angina, electrocardiogram abnormalities) was clearlynotdose-ormedication-related,affecting1% (2/157),6%(9/158),and4%(3/78)ofthepatientsin the 5% topical minoxidil, 2% topical minoxidil, and placebogroups,respectively.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The occurrence of cardiovascular adverse events (ie, chest pain, palpitations, increase in blood pres- sure, angina, electrocardiogram abnormalities) was clearlynotdose-ormedication-related,affecting1% (2/157),6%(9/158),and4%(3/78)ofthepatientsin the 5% topical minoxidil, 2% topical minoxidil, and placebogroups,respectively.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Headache was the only other drug-related ad- verse event that occurred in more than one patient within at least one treatment group: 5 (3%) of the 157 patients in the 5% topical minoxidil group, in- cluding one who dropped out because of this ad- verse event, 1 (0.6%) of the 158 patients in the 2% topical minoxidil group, and 1 (1%) of the 78 pa- tients in the placebo group.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Headache was the only other drug-related ad- verse event that occurred in more than one patient within at least one treatment group: 5 (3%) of the 157 patients in the 5% topical minoxidil group, in- cluding one who dropped out because of this ad- verse event, 1 (0.6%) of the 158 patients in the 2% topical minoxidil group, and 1 (1%) of the 78 pa- tients in the placebo group.

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The most frequent drug- related dermatologic event was pruritus, affecting 6 (4%) of 157 patients in the 5% topical minoxidil group, 2 (1%) of 158 patients in the 2% topical minoxidil group, and no patients in the placebo group. Five patients in the 5% topical minoxidil

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The most frequent drug- related dermatologic event was pruritus, affecting 6 (4%) of 157 patients in the 5% topical minoxidil group, 2 (1%) of 158 patients in the 2% topical minoxidil group, and no patients in the placebo group. Five patients in the 5% topical minoxidil

Olsen EA, Dunlap FE, Funicella T et al.. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. J Am Acad Dermatol 2002, DOI 10.1067/mjd.2002.124088. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table I. Pvalues from Fisher least significant difference placebo (5-P)* Mean percentage weight change Week 2-5 2-P 5-P 2-5 6 .606 .002 .005 .470 12 .073 .055 0 .072 18 .019 .064 0 .033 24 .360 .008 0 .914 30 .578 .039 .007 .859 36 .321 .171 .016 .154 42 .172 .074 .002 .572 48 .405 .011 .001 .492 54 .158 .081 .002 .075 60 .301 .094 .007 .585 66 .873 .014 .014 .364 72 .392 .007 0 .124 78 .081 .024 0 .308 84 .236 .013 0 .653 90 .055 .025 .003 .605 96 .437 .005 0 .455

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment.. J Am Acad Dermatol 1999, DOI 10.1016/s0190-9622(99)70006-x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table I. Pvalues from Fisher least significant difference placebo (5-P)* Mean percentage weight change Week 2-5 2-P 5-P 2-5 6 .606 .002 .005 .470 12 .073 .055 0 .072 18 .019 .064 0 .033 24 .360 .008 0 .914 30 .578 .039 .007 .859 36 .321 .171 .016 .154 42 .172 .074 .002 .572 48 .405 .011 .001 .492 54 .158 .081 .002 .075 60 .301 .094 .007 .585 66 .873 .014 .014 .364 72 .392 .007 0 .124 78 .081 .024 0 .308 84 .236 .013 0 .653 90 .055 .025 .003 .605 96 .437 .005 0 .455

Citation complémentaire (significativite)

*0 represents P< .0005; (P> .05),nonsignificant.Analysis of variance intergroup tests are italicized.

Price VH, Menefee E, Strauss PC. Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5% and 2% topical minoxidil, placebo, or no treatment.. J Am Acad Dermatol 1999, DOI 10.1016/s0190-9622(99)70006-x. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).